Drug Trial Radar · NCT03605667
Study of BHV-4157 in Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Dec 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Actual
Start
Jul 31, 2018
Primary completion
Dec 15, 2020
Study completion Dec 23, 2021
Sponsor
- Lead sponsor
- Biohaven Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Alzheimer's Disease Cooperative Study (ADCS)
- First posted
- Jul 30, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Preclinical models suggest that riluzole, the active metabolite of BHV-4157, may protect from AD-related pathology and cognitive dysfunction. Titrated dose of BHV-4157 to 280 mg, or placebo, were administered orally once daily. Duration of treatment is 48 weeks in double-blind phase. There is also a screening period of up to 42 days; and a 4-week post-treatment observation period. Eligible participants who completed the double-blind treatment phase had the opportunity to receive open-label troriluzole for up to 48 weeks in an open-label extension (OLE) phase.
Conditions
- Alzheimer Disease
Interventions
troriluzoleDrug
Oral BHV-4157 will be given daily for up to 48 weeks
Placebo oral capsuleDrug
Oral matching placebo will be given daily for up to 48 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) Total Score at Week 48Time frame: Baseline (Day 1) and Week 48
- Change From Baseline in Clinical Dementia Rating-Sum of Boxes (CDR-Sum of Boxes) Total Score at Week 48Time frame: Baseline (Day 1) and Week 48
Locations
44 sites in 1 country. Site status is shown where the registry gives one.
Xenoscience, Inc.
Phoenix, Arizona
Barrow Neurological Institute
Phoenix, Arizona
Banner Sun Health Research Institute
Sun City, Arizona
Neurology Center of North Orange County
Fullerton, California
University of California, San Diego
La Jolla, California
University of Southern California
Los Angeles, California
SC3 Research Group - Pasadena
Pasadena, California
Geriatric and Adult Psychiatry
Hamden, Connecticut
Yale University School of Medicine
New Haven, Connecticut
Ki Health PARTNERS LLC DBA NEW ENGLAND INSTITUTE FOR CLINICAL RESEARCH
Stamford, Connecticut
Brain Matters Research
Delray Beach, Florida
University of Miami
Miami, Florida
USF Health Byrd Alzheimer's Institute
Tampa, Florida
Northwestern University
Chicago, Illinois
Great Lakes Clinical Trials
Chicago, Illinois
Southern Illinois University
Springfield, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Kentucky
Lexington, Kentucky
Pennington Biomedical Research Center
Baton Rouge, Louisiana
Northern Light Acadia Hospital
Bangor, Maine
Johns Hopkins University
Baltimore, Maryland
University of Michigan, Ann Arbor
Ann Arbor, Michigan
Michigan State University
East Lansing, Michigan
Galen Research
Chesterfield, Missouri
Cleveland Clinic Lou Ruvo Center
Las Vegas, Nevada
Princeton Medical Institute
Princeton, New Jersey
Columbia University
New York, New York
University of Rochester Medical Center
Rochester, New York
SUNY Upstate Medical University Department of Geriatrics
Syracuse, New York
James J. Peters VAMC
The Bronx, New York
Case Western Reserve University
Beachwood, Ohio
Ohio State University
Columbus, Ohio
Tulsa Clinical Research
Tulsa, Oklahoma
Oregon Health and Science University
Portland, Oregon
Keystone Clinical Studies, LLC
Norristown, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
Geisinger Medical Clinic
Wilkes-Barre, Pennsylvania
Abington Neurological Associates
Willow Grove, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.